Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Metabolism of GLPG1690 in Healthy Males
NCT03787186Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Nov 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ziritaxestat in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Galapagos NV. Primary endpoints: Change of total radioactivity excreted in urine and feces combined at Day 10, Maximum observed plasma concentration (Cmax) of total radioactivity at Day 10 and 3 more. Started Nov 2018; status: completed.
02
Drugs
ziritaxestat
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03787186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03787186.